|
[1] COLLINS FS,VARMUS H.A new initiative on precision medicine[J].N Engl Med,2015,372(9):793-795.
|
|
[2]JAMESON JL,LONGO DL.Precision medicine---personalized,problematic,and promising[J].N Engl Med,2015,372(23):2229-2234.
|
|
[3]MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342.
|
|
[4]MAJUMDAR A,KITSON MT,ROBERTS SK.Systematic review:current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis[J].Aliment Pharmacol Ther,2016,43(12):1276-1292.
|
|
[5]GUTIERREZ JA,LAWITZ EJ,POORDAD F.Interferon-free,direct-acting antiviral therapy for chronic hepatitis C[J].Viral Hepat,2015,22(11):861-870.
|
|
[6]RAO H,WEI L,LOPEZ-TALAVERA JC,et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol,2014,29(3):545-553.
|
|
[7]LEE MH,YANG HI,LU SN,et al.Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases:a community-based long-term prospective study[J].J Infect Dis,2012,206(4):469-477.
|
|
[8]LEE MH,YANG HI,LU SN,et al.Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer,2014,135(5):1119-1126.
|
|
[9]WEI L.Present situation of hepatitis C virus antiviral therapy and application prospects of small molecule drugs in our country[J].Chin J Hepatol,2013,21(6):403-405.魏来.我国丙型肝炎抗病毒治疗现状与小分子药物的应用前景[J].中华肝脏病杂志,2013,21(6):403-405.
|
|
[10]YU ML,DAI CY,HUANG JF,et al.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients:a rondomized trial[J].Hepatology,2008,47(6):1884-1893.
|
|
[11]HUANG CF,YANG JF,HUANG JF,et al.Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response[J].J Gastroenterol Hepatol,2010,25(4):758-765.
|
|
[12]SWAIN MG,LAI MY,SHIFFMAN ML,et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin[J].Gastroenterology,2010,139(5):1593-1601.
|
|
[13]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学会分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.
|
|
[14]OMATA M,KANDA T,WEI L,et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int,2016.[Epub ahead of print]
|
|
[15]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol,2015,63(1):199-236.
|
|
[16]WANG J,JIN Q,RAO HY,et al.Comparison of domestic reagents and Roche COBAS Taq Man in rapid and early virological response in patients with chronic hepatitis C[J].Infect Dis Info,2012,25(3):177-179.(in Chinese)王剑,金茜,饶慧瑛,等.国产试剂与Roche COBAS Taq Man试剂对慢性丙型肝炎快速和早期病毒学应答的比较研究[J].传染病信息,2012,25(3):177-179.
|
|
[17]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection:updated version[EB/OL].http://www.who.int/publications/guidelines/en/
|
DownLoad: